Blood Cancers (Lymphoma, Leukemia, Myeloma)

Blood cancers affect the bone marrow, lymphatic system, and blood-forming tissues and require prompt, specialised care. Our Haemato-Oncology team provides comprehensive diagnosis, evidence-based treatment, and long-term supportive care for lymphoma, leukemia, and multiple myeloma, using the latest targeted therapies, immunotherapies, and transplantation techniques to maximise survival and quality of life.

Our multidisciplinary team of hematologists, medical oncologists, transfusion specialists, pathologists, and supportive-care experts work together to create personalised treatment plans that address both disease control and patient wellbeing.

Understanding Blood Cancers

Blood cancers originate from abnormal growth of blood-forming cells in the bone marrow or cells of the lymphatic system. Each type has unique biology and treatment pathways, so accurate classification is essential.

Leukemia

Leukemia begins in the bone marrow or blood with uncontrolled proliferation of immature or dysfunctional white blood cells. It can present as acute (rapid onset) or chronic (slower progressing) forms and requires subtype-specific therapy.

Lymphoma

Lymphoma arises in the lymphatic system and is broadly classified into Hodgkin lymphoma and non-Hodgkin lymphoma, with numerous subtypes each requiring distinct diagnostic and treatment approaches.

Multiple Myeloma

Myeloma affects plasma cells in the bone marrow, often causing bone pain, anaemia, kidney dysfunction, and immune compromise; modern regimens and transplant options can produce long remissions.

Common Symptoms

Symptoms can be subtle or nonspecific. Patients may experience:

Persistent fatigue or weakness
Frequent or severe infections
Unexplained weight loss
Swollen lymph nodes or painless lumps
Bone pain or pathological fractures
Fever, night sweats, or persistent fevers
Easy bruising, bleeding, or unexplained anemia

Timely evaluation by a hematologist is important when these symptoms occur.

Accurate Diagnosis

We employ a full range of diagnostic tests to precisely characterise the disease and guide therapy:

Complete blood count and peripheral smear
Bone marrow aspiration and biopsy with histopathology
Immunophenotyping and flow cytometry
Cytogenetic and molecular/genomic testing
Advanced imaging such as PET-CT and MRI for staging
Laboratory assessments for organ function and infection screening

Treatment Options

Treatment is individualised according to diagnosis, stage, patient fitness, and molecular markers. Our evidence-based options include:

Chemotherapy using modern regimens tailored to disease subtype
Immunotherapy and monoclonal antibodies targeting specific cancer cells
Targeted small-molecule therapies based on genetic abnormalities
CAR T-cell therapy for eligible relapsed/refractory cases (where available)
Stem cell (autologous or allogeneic) transplantation for curative intent in selected patients
Supportive care including transfusions, infection prevention, and growth factors

Post-Treatment Care

Long-term monitoring and supportive measures are key to recovery and surveillance:

Structured follow-up schedules with blood tests and imaging
Infection prevention strategies, vaccinations, and prophylaxis
Nutritional guidance and rehabilitation support
Psychological counselling and survivorship planning

Benefits of Personalised Haemato-Oncology Care

Precision Treatment: Therapies targeted to molecular and cytogenetic features.
Improved Tolerability: Supportive care reduces treatment-related complications.
Better Outcomes: Modern protocols and transplantation improve remission rates.
Holistic Support: Emphasis on quality of life, infection control, and rehabilitation.

Who Can Benefit?

Our services are appropriate for patients with:

Acute or chronic leukemias
Hodgkin and non-Hodgkin lymphomas
Multiple myeloma and plasma cell disorders
Relapsed or refractory disease requiring advanced therapies
Patients requiring stem cell transplantation or cellular therapies

Individual assessment ensures each patient receives the safest and most effective plan.

The Treatment Process

Comprehensive Evaluation: Blood tests, bone marrow studies, imaging, and molecular profiling.
Multidisciplinary Planning: Tailored treatment strategy devised by hematology, transplant, pharmacy, and supportive-care teams.
Treatment Delivery: Chemotherapy, targeted agents, immunotherapy, CAR T or transplant as appropriate.
Monitoring & Support: Frequent labs, infection surveillance, transfusions, and rehabilitation during recovery.

Frequently Asked Questions (FAQs)

Q1. Can blood cancers be cured?
Many blood cancers are curable, particularly certain leukemias and lymphomas, while others can be controlled long-term with modern therapies; transplant may offer curative potential for selected patients.

Q2. What is CAR T-cell therapy?
CAR T-cell therapy is a personalised immunotherapy where a patient’s own T cells are modified to target cancer; it is used for specific relapsed or refractory blood cancers.

Q3. Is stem cell transplant the same as a bone marrow transplant?
Yes, stem cell transplant (autologous or allogeneic) replaces diseased marrow with healthy stem cells and may be used for curative or consolidation purposes.

Q4. How do you manage infections during treatment?
Infection prevention includes prophylactic medications, vaccinations when appropriate, strict monitoring, and prompt treatment of fevers and suspected infections.

Why Choose Our Haemato-Oncology Program?

Experienced hematologists and transplant physicians
Dedicated infusion, transplant, and cellular therapy units
Comprehensive laboratory and molecular diagnostics
Access to cutting-edge protocols and clinical trials
Compassionate, patient-centred care with strong supportive services

Take the First Step Toward Recovery

Blood cancers are often treatable, early diagnosis and the right care matter. If you are experiencing concerning symptoms or have been advised to seek specialist evaluation, schedule your consultation now.